MedImmune Signs Cancer Pact with Immunocore - - BioPharm International

ADVERTISEMENT

MedImmune Signs Cancer Pact with Immunocore


p>MedImmune, the biologics R&D arm of AstraZeneca, has entered into a cancer research collaboration with UK-based biotech company Immunocore. Under the terms of the licensing agreement, both companies will conduct research to develop novel cancer therapies using Immunocore’s Immune Mobilising Monoclonal T-Cell Receptor Against Cancer (ImmTAC) technology. The platform harnesses the patient’s immune system by directing T cells to target and destroy cancerous cells without damaging healthy cells. Immunocore and MedImmune will work together to generate ImmTACs against selected cancer targets.

AstraZeneca and MedImmune will have rights to further develop and commercialize ImmTAC products. Immunocore will receive an upfront payment of $20 million per program and is eligible to receive up to $300 million in development and commercial milestone payments for each target program and significant tiered royalties from successful programs.

Source: AstraZeneca

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

AbbVie/Shire Deal Officially Off
October 20, 2014
Amgen Sues Sanofi and Regeneron over Patent for mAb Targeting PCSK9
October 20, 2014
EMA Works to Speed Up Ebola Treatment
October 20, 2014
Lilly to Close Manufacturing Facility in Puerto Rico
October 17, 2014
BioReliance Introduces New Predictive Assays
October 17, 2014
Author Guidelines

Click here